Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 184Magnetic Resonance Spectroscopy 162Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 93Radiosurgery 91Prednisone 81Androgen Antagonists 80Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 63Ipilimumab 61Biopsy 61abiraterone 58cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 51Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37olaparib 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prodrugs × Genitourinary × 1 year × Clear all
NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡